Back to results
US 7,842,480 B2Granted
Chimeric antigen-specific t cell-activating polypeptides
AssigneeMayo Foundation for Medical Education and Research
InventorEsteban Celis
Life of this patent
Estimating the term…
Abstract
The invention provides an immunogenic or antigenic polypeptide containing a translocation domain, a peptide epitope, at least one biologically active agent, and cleavage sites. These polypeptides are useful for activating T cell responses.
Claims20
A fusion agent comprising:
- (a) a transport domain;
- (b) at least two cleavage sites;
- (c) a first peptide epitope recognized by an antigen specific receptor on an effector T lymphocyte or on an effector T lymphocyte precursor cell;
- and
- (d) at least one additional peptide epitope recognized by an antigen specific receptor on an effector T lymphocyte or on an effector T lymphocyte precursor cell,
- wherein each of the peptide epitopes in the fusion agent is 7-40 amino acids in length and there is a cleavage site between each of the peptide epitopes in the fusion agent.
3 more elements
A fusion agent comprising:
- (a) a transport domain;
- (b) at least two cleavage sites;
- (c) a first peptide epitope recognized by an antigen specific receptor on an effector T lymphocyte or on an effector T lymphocyte precursor cell;
- and
- (d) at least one additional peptide epitope recognized by an antigen specific receptor on an effector T lymphocyte or on an effector T lymphocyte precursor cell,
- wherein the transport domain is at the N terminus or at the C terminus of the fusion agent and there is a cleavage site between each of the peptide epitopes in the fusion agent.
3 more elements
Dependencies are inferred from the claim text.